MichaelTLotzeMD
General Surgery • Pittsburgh, PAMelanoma
Professor, Surgery, University of Pittsburgh School of Medicine
Dr. Lotze is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
200 Lothrop Street
Hillman Cancer Center
Pittsburgh, PA 15213Phone+1 412-770-9910- Is this information wrong?
Education & Training
University of RochesterResidency, Surgery, 1980 - 1982- University of RochesterResidency, Surgery, 1975 - 1977
Northwestern University The Feinberg School of MedicineClass of 1974
Certifications & Licensure
PA State Medical License 1990 - 2024
Awards, Honors, & Recognition
- Fellow (FACS) American College of Surgeons
Clinical Trials
- Study of Hydroxychloroquine Before Surgery in Patients With Primary Renal Cell Carcinoma Start of enrollment: 2010 Oct 01
- Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC) Start of enrollment: 2012 Mar 01
Publications & Presentations
PubMed
- SITC Clinical Immuno-Oncology Network (SCION) commentary on measurement and interpretation of essential biomarkers in early clinical trials.Tricia Cottrell, Laura Chow, Leslie Cope, Sacha Gnjatic, Holden T Maecker, Joe Yeong Poh Shen, Michael T Lotze, Carlo Bifulco> ;Journal for Immunotherapy of Cancer. 2024 Mar 21
- Rapamycin mitigates inflammation-mediated disc matrix homeostatic imbalance by inhibiting mTORC1 and inducing autophagy through Akt activation.Yurube, T., Buchser, W., Zhang, Z., Silwal, P., Sowa, G., Vo, N., Lotze, M., Kang, J.> ;JOR Spine. 2024 Mar 1
- Impact of Recombinant Granulocyte Colony-Stimulating Factor During Neoadjuvant Therapy on Outcomes of Resected Pancreatic Cancer.Murthy, P., Zenati, M., AlMasri, S., DeSilva, A., Singhi, A., Paniccia, A., Lee, K., Simmons, R., Bahary, N., Lotze, M., Zureikat, A.> ;Journal of the National Comprehensive Cancer Network. 2023 Dec 27
- Join now to see all
Press Mentions
ACGT Scientific Advisory Council Chair Michael T. Lotze, MD, Honored with Lifetime Achievement Award from Society for Immunotherapy of CancerNovember 5th, 2021- Chutes & Ladders—Novavax Appoints AstraZeneca Vet Dubovsky to CMO RoleJune 19th, 2020
- Boehringer Ingelheim Nabs New US President and CEO; AstraZeneca Vet Hops Aboard Novavax as CMOJune 19th, 2020
- Join now to see all
Grant Support
- IL-1 Homologues Promote The Acute Inflammatory Response To MelanomaNational Cancer Institute2007–2009
- Integrating NK And DC Into Cancer TherapyNational Cancer Institute2005–2009
- IL-1 Homologues Promote The Acute Inflammatory ResponseNational Cancer Institute2005–2006
- Administrative CoreNational Cancer Institute2005
- Apoptotic Pathways Following Chemotherapy Or Gene Therapy Of Oral CancerNational Institute Of Dental &Craniofacial Research1999–2002
- Random Evaluation Of Immunization Of Patients With Metastatic MelanomaNational Center For Research Resources1999–2002
- Phase 2 Study Of FLT3 Ligand (FLT3) In Metastatic Melanoma PatientsNational Center For Research Resources1999–2002
- Immunization For Metastatic Melanoma With Dendritic CellsNational Center For Research Resources1999–2002
- Biological Therapeutics ProgramNational Cancer Institute1999–2002
- Phase I Melan A/Mart 1 GP100 Trial In Metastatic MelanomaNational Center For Research Resources1998–2002
- Dendritic Cell Therapies Elicit Effective Antitumor ResponsesNational Cancer Institute1998–2002
- Dendritic Cell Therapy For Hiv--Role Of Cytokines On Enhanced T Cell FunctionNational Institute Of Allergy And Infectious Diseases1998–2001
- Oral Carcinoma Treatment--Interleukin 12 And Gene TherapyNational Institute Of Dental &Craniofacial Research1997–2001
- Gene Transfection To Enhance Dendritic And Endothelial Cell FunctionNational Cancer Institute1996–2001
- Dendritic Cell Biology And TherapyNational Cancer Institute1998–2000
- Phase II Study Of FLT3 Ligand In Metastatic Melanoma PatientsNational Center For Research Resources1999
- Phase I/II Study Of Immunization In Melanoma Using Dendritic CellsNational Center For Research Resources1999
- Clinical Trials Of Biological Response ModifiersNational Cancer Institute1996–1999
- Cytokine Gene Therapy Of CancerNational Cancer Institute1995–1999
- Biologic Therapy Research Career Development ProgramNational Cancer Institute1997–1998
- Dendritic Cells Elicit Effective Antitumor ResponsesNational Cancer Institute1997
- Conference On Cellular Immunology Of CancerNational Cancer Institute1997
- Phase III Trial To Evaluate The Efficacy Of Recombinant Human GM-CSFNational Center For Research Resources1996–1997
- Clinical Trials Of Biological Response ModifiersDivision Of Cancer Treatment1995–1997
- Phase I Dose-Escalating Study Of Recombinant Human Interleukin-12National Center For Research Resources1996
- Phase I Dose-Escalating Study Of Recombinant Human Interleukin 12National Center For Research Resources1996
- In Vivo Testing Of The Immune Response To Tumor MucinNational Center For Research Resources1996
- Gene Therapy Of Cancer--Pilot Study Of IL-4 Gene Modified Tumor VaccineNational Center For Research Resources1996
- Interleukin 12--Immunology Of A Regulatory CtyokineNational Cancer Institute1995
- Locoregional AIT With Autologous IL2 Activated NK CellsNational Cancer Institute1994–1995
- Locoregional AIT With Autologous Il2-Activated NK CellsNational Cancer Institute1992–1993
- Gene Therapy Of Cancer-Immunological ApproachesNational Cancer Institute1992–1993
- T Cell Receptor Usage In Melanoma And Its PrecursorsNational Cancer Institute1992
Professional Memberships
- Member
Hospital Affiliations
UPMC Presbyterian ShadysidePittsburgh, Pennsylvania
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
